NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1508.90 16.30 (1.09%)

926.4K NSE+BSE Volume

NSE 18 Mar, 2025 12:39 PM (IST)

121,861

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Search Inside the pdf :

Cipla Ltd.

29 Jan 2025

1508.90

1.09%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We maintain our BUY recommendation with a target price of Rs 1,700/share.

Cipla Ltd. is trading above its 100 day SMA of 1477.6

Cipla Ltd.

29 Jan 2025

1508.90

1.09%

CIPLA LTD.

Buy: Cipla Ltd.

Prabhudas Lilladhar

Cipla Ltd. has an average target of 1707.30 from 11 brokers.

Cipla Ltd.

28 Jan 2025

1508.90

1.09%

3Q results beat estimates; yet to scale up Lanreotide supply

Neutral: Cipla Ltd.

Recommendation Target

Motilal Oswal

CIPLA delivered better-than-expected 3QFY25 earnings. While revenue was in line, EBITDA/adj. PAT beat our estimates, aided by a better product mix and lower R&D spending.

Cipla Ltd. has an average target of 1707.30 from 11 brokers.

Cipla Ltd.

17 Jan 2025, 12:00AM

1508.90

1.09%

Empowering health, Enriching Lives

Accumulate: Cipla Ltd.

Asit C Mehta Investment Interrmediates

Cipla's "Future Fit" strategy outlines ambitious growth objectives, including becoming India’s 2nd largest pharmaceutical company, leading South Africa’s prescription and OTC markets, ranking 2nd in U.S. respiratory generics, and doubling international revenue.

Cipla Ltd. is trading above its 100 day SMA of 1477.6

Cipla Ltd.

04 Dec 2024

1508.90

1.09%

CIPLA LTD

Buy: Cipla Ltd.

Target

Geojit BNP Paribas

Cipla Ltd.'s price crossed above 100Day SMA today

Cipla Ltd.

28 Nov 2024

1508.90

1.09%

CIPLA LTD.

Buy: Cipla Ltd.

Recommendation Target

Prabhudas Lilladhar

Cipla Ltd.'s price crossed above 100Day SMA today

Cipla Ltd.

04 Nov 2024

1508.90

1.09%

New launches and strong market expansion will drive top-line growth

Accumulate: Cipla Ltd.

Target

KRChoksey

Cipla’s revenue was largely in-line with our estimates (-2.0%), EBITDA was in-line (+0.2%) and Adj. PAT beat our estimates (+3.4%) due to lower-than-expected finance costs and higher-than-expected other income.